Rate My Professor Takashi Tenma

Takashi Temma, Professor in the Department of Biofunctional Analysis in the Faculty of Pharmacy at Osaka University of Pharmaceutical Sciences from 2017 to 2021, holds a PhD in Pharmaceutical Sciences from Kyoto University, obtained in November 2008. He completed his undergraduate studies at Kyoto University Faculty of Pharmaceutical Sciences in 2000, followed by a Master's degree in 2002 from the Graduate School of Pharmaceutical Sciences. Prior to his appointment at Osaka University of Pharmaceutical Sciences, Temma served as Assistant Professor in the Department of Patho-Functional Bioanalysis at Kyoto University's Graduate School of Pharmaceutical Sciences from 2004 to 2014, and as Laboratory Chief in the Department of Investigative Radiology at the National Cerebral and Cardiovascular Center Research Institute from 2014 to 2017. His career also includes a visiting researcher position at the Turku PET Centre, University of Turku in 2013.

Temma's research specializes in the development of imaging probes for positron emission tomography (PET), single photon emission computed tomography (SPECT), and fluorescence imaging, with a focus on boron neutron capture therapy (BNCT), tumor-specific delivery, and theranostics targeting pathways such as LAT1, p38α, and STAT3. Notable publications include "A LAT1-selective PET tracer, 5-[¹⁸F]F-αMe-3BPA, as a companion to its structurally matched ¹⁰B analog in boron neutron capture therapy" (Kondo et al., European Journal of Nuclear Medicine and Molecular Imaging, 2026), "Fluorine-18-Labeled Positron Emission Tomography Probe Targeting Activated p38α: Design, Synthesis, and In Vivo Evaluation in Rodents" (Futatsugi et al., Pharmaceuticals, 2025), "Assessing the effectiveness of fluorinated and α-methylated 3-boronophenylalanine for improved tumor-specific boron delivery in boron neutron capture therapy" (Hirano et al., Bioorganic Chemistry, 2024), and "Synthesis and evaluation of [18F]FBNAF, a STAT3-targeting probe, for PET imaging of tumor microenvironment" (Miyazaki et al., EJNMMI Radiopharmacy and Chemistry, 2024). He has received prestigious awards such as the Springer Nature Editor of Distinction Award (2025), Certificate of Commendation from GlaxoSmithKline K.K. (2019), Japan Brain Neuro-Nuclear Medicine Research Encouragement Award (2016), and SNMMI 62nd Annual Meeting Poster Award (2015). Temma has been principal investigator on multiple JSPS Grants-in-Aid for Scientific Research, including projects on BNCT agents and Cherenkov light-driven molecular machines during his time at Osaka University of Pharmaceutical Sciences. He holds editorial and directorial roles in societies like the Japanese Society of Nuclear Medicine and Japan Molecular Imaging Society, contributing to the field of nuclear medicine and pharmaceutical sciences.